BerGenBio

Report Publication Announcement • Feb 6, 2018

BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast

Bergen, Norway, 06 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the fourth quarter and full year 2017 on Tuesday, 13 February 2018.

A presentation by BerGenBio's senior management team will take place at 10.00 am CET at:

Felix Konferansesenter, Bryggetorget 3, 0125 Oslo

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day.

-Ends-

Contacts
Richard Godfrey
CEO, BerGenBio ASA
media@bergenbio.com
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
tom.sundby@bergenbio.com
+47 477 54 415
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedr.co.uk
+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.